1) Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008; 300(24): 2867-78.
2) Yamazaki H. Drug interaction studies in the 21st century: research into cytochrome P450s, transporters, and simulations informing their role in drug-drug interactions. Drug Metab Pharmacokinet. 2007; 22(4): 223-4.
3) Sugiyama M, Fujita K, Murayama N, Akiyama Y, Yamazaki H, Sasaki Y. Sorafenib and sunitinib, two anti-cancer drugs, inhibit CYP3A4-mediated and activate CYP3A5-mediated midazolam 1'-hydroxylation. Drug Metab Dispos. 2011; 39(5): 757-62.
4) Yamazaki H, Suemizu H, Murayama N, Utoh M, Shibata N, Nakamura M, et al. In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice. Chem Res Toxicol. 2013; 26(3): 486-9.
5) Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011; 89(5): 735-40.